


# Product Data Sheet

## PF-04449913

<b>Cat. No.:</b>	B3283
<b>CAS No.:</b>	1095173-27-5
<b>Formula:</b>	C <sub>21</sub> H <sub>22</sub> N <sub>6</sub> O
<b>M.Wt:</b>	374.44
<b>Synonyms:</b>	
<b>Target:</b>	Stem Cell
<b>Pathway:</b>	Smoothened
<b>Storage:</b>	Store at -20°C



### Solvent & Solubility

≥20.15 mg/mL in DMSO; insoluble in H<sub>2</sub>O; ≥9.36 mg/mL in EtOH

In Vitro	Preparing Stock Solutions	Mass			
		Solvent	1mg	5mg	10mg
		<b>Concentration</b>			
		<b>1 mM</b>	2.6707 mL	13.3533 mL	26.7065 mL
		<b>5 mM</b>	0.5341 mL	2.6707 mL	5.3413 mL
		<b>10 mM</b>	0.2671 mL	1.3353 mL	2.6707 mL

Please refer to the solubility information to select the appropriate solvent.

### Biological Activity

Shortsummary	Antagonist of smoothened	
IC <sub>50</sub> & Target		
In Vitro	<b>Cell Viability Assay</b>	
	Preparation method:	
In Vivo	<b>Animal experiment</b>	
	Animal models:	Rats and dogs
	Dosage form:	1 mg/kg and 0.5 mg/kg, Oral dosing
	Applications:	In rats and dogs, PF-04449913 had high clearance in rat and low clearance in

dog with CL of 31 and 3.9 mL/min/kg, respectively. The oral bioavailabilities of PF-04449913 in rat and dog were 33 and 68%, respectively. PF-04449913 had moderate volume distribution of 4.8 and 4.3 L/kg and t<sub>1/2</sub> of 1.4 and 2.9 h, respectively.

Other notes:

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1] Munchhof MJ, Li Q, Shavnaya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT. Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothed. ACS Med Chem Lett. 2011 Dec 21;3(2):106-11.

[2]. Wagner AJ1, Messersmith WA2, Shaik MN3, et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 1;21(5):1044-51.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

*Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.*

**APExBIO Technology**

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

2 | [www.apexbt.com](http://www.apexbt.com)



